Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 2/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | HCRTR1 | O43613 | 11/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.38 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.36 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.36 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31313196 | 0.91 | FAAH (0.40) | FAAHCNR2HCRTR1 | |
| SCHEMBL26906355 | 0.80 | ALDH1A1 (0.50) | FAAHCNR2TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL29953732 | 0.77 | HCRTR1 (0.35) | HCRTR1HCRTR2 | |
| SCHEMBL31313163 | 0.77 | SIK1 (0.39) | FAAHCNR2HCRTR1 | |
| SCHEMBL31313285 | 0.77 | SIK1 (0.39) | FAAHCNR2HCRTR1 | |
| SCHEMBL22726772 | 0.76 | SIK1 (0.37) | HCRTR1HCRTR2 | |
| SCHEMBL29954128 | 0.76 | SIK1 (0.37) | HCRTR1HCRTR2 | |
| SCHEMBL22714935 | 0.75 | HCRTR1 (0.47) | HCRTR1HCRTR2 | |
| SCHEMBL21591068 | 0.75 | ALDH1A1 (0.46) | FAAHTAS1R3TAS1R1TAS1R2DRD3 | |
| SCHEMBL21593325 | 0.74 | DRD3 (0.47) | TAS1R3TAS1R1TAS1R2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12391679-B2 | Benzamide-substituted bicyclic imidazo- and pyrazolo-fused -pyridine, -pyrimide, and -pyridazine compounds for treatment of inflammatory diseases | ONCO3R THERAPEUTICS BV (BE) | 2025-08-19 | — | — | US | disclosed |
| EP-3976189-B1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES | GALAPAGOS NV (BE) | 2024-07-03 | — | — | EP | disclosed |
| US-20220340548-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES | GALAPAGOS NV (BE) | 2022-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220340548-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES | IL1B, IL1A, IL36G | FAAH 2470/4885CNR2 1387/4885HCRTR1 903/4885 |
| US-12391679-B2 | Benzamide-substituted bicyclic imidazo- and pyrazolo-fused -pyridine, -pyrimide, and -pyridazine compounds for treatment of inflammatory diseases | IL5, IL15, IL1A | FAAH 2544/4885CNR2 1128/4885HCRTR1 1679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.